Hormonal therapy plus radiation increases survival in node-positive prostate cancer
the ONA take:
According to a new study published online in the Journal of the National Cancer Institute, researchers from the American Cancer Society and Massachusetts General Hospital Cancer Center in Boston have found that the addition of radiotherapy to hormonal therapy may improve survival in men with node-positive prostate cancer who are at significant risk of cancer-related death.
The study showed that approximately half of patients with node-positive prostate cancer in the United States who had not received combined radiation therapy and hormonal therapy and were therefore not receiving the treatment that could best inhibit tumor growth and improve survival.
"Our analysis of a large national database revealed that adding radiation therapy to androgen-deprivation therapy decreased the risk of death in these patients by 50 percent over five years," says Jason Efstathiou, MD, DPhil, of the MGH Cancer Center and Department of Radiation Oncology, senior author of the study.
Researchers found that more aggressive local management of prostate cancer that is limited to the pelvis can result in more durable disease control, limit cancer metastasis, and potentially cure some patients.
Addition of radiotherapy to hormonal therapy may improve survival in men with node-positive prostate cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|